cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…

1 month ago

Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer

Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of…

1 month ago

International Cancer Organizations Present Collaborative Work During Oncology Event in China

The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…

1 month ago

International Cancer Organizations Present Collaborative Work During Oncology Event in China

The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…

1 month ago

International Cancer Organizations Present Collaborative Work During Oncology Event in China

The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…

1 month ago

International Cancer Organizations Present Collaborative Work During Oncology Event in China

The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…

1 month ago

KFSHRCs New US Patent Opens New Frontiers for Breast Cancer Treatment

RIYADH, Saudi Arabia, Nov. 10, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) announced a significant…

1 month ago

Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting…

1 month ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected…

1 month ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…

1 month ago